<?xml version="1.0" encoding="UTF-8" standalone="no"?>

<MINiML
   xmlns="http://www.ncbi.nlm.nih.gov/geo/info/MINiML"
   xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
   xsi:schemaLocation="http://www.ncbi.nlm.nih.gov/geo/info/MINiML http://www.ncbi.nlm.nih.gov/geo/info/MINiML.xsd"
   version="0.5.0" >

  <Contributor iid="contrib1">
    <Person><First>FRANCOIS</First><Last>Patrice</Last></Person>
    <Department>Division of Infectious Diseases</Department>
    <Organization>Genomic Research Laboratory</Organization>
    <Address>
      <Line>Rue Gabrielle-Perret-Gentil, 4  </Line>
      <City>Geneva</City>
      <Postal-Code>1211</Postal-Code>
      <Country>Switzerland</Country>
    </Address>
    <Web-Link>www.genomic.ch</Web-Link>
  </Contributor>

  <Contributor iid="contrib2">
    <Person><First>Patrice</First><Last>Francois</Last></Person>
  </Contributor>

  <Contributor iid="contrib3">
    <Person><First>Antoine</First><Last>Huyghe</Last></Person>
  </Contributor>

  <Contributor iid="contrib4">
    <Person><First>Jacques</First><Last>Schrenzel</Last></Person>
  </Contributor>

  <Contributor iid="contrib5">
    <Person><First>Adrien</First><Last>Fischer</Last></Person>
  </Contributor>

  <Contributor iid="contrib6">
    <Person><First>Soo-Jin</First><Last>Yang</Last></Person>
  </Contributor>

  <Contributor iid="contrib7">
    <Person><First>Arnold</First><Middle>S</Middle><Last>Bayer</Last></Person>
  </Contributor>

  <Contributor iid="contrib8">
    <Person><First>Ali</First><Middle>R</Middle><Last>Vaezzadeh</Last></Person>
  </Contributor>

  <Contributor iid="contrib9">
    <Person><First>Sébastien</First><Last>Herzig</Last></Person>
  </Contributor>

  <Contributor iid="contrib10">
    <Person><First>Ludwig</First><Last>Stenz</Last></Person>
  </Contributor>

  <Contributor iid="contrib11">
    <Person><First>Myriam</First><Last>Girard</Last></Person>
  </Contributor>

  <Contributor iid="contrib12">
    <Person><First>George</First><Last>Sakoulas</Last></Person>
  </Contributor>

  <Contributor iid="contrib13">
    <Person><First>Alexander</First><Last>Scherl</Last></Person>
  </Contributor>

  <Contributor iid="contrib14">
    <Person><First>Michael</First><Middle>R</Middle><Last>Yeaman</Last></Person>
  </Contributor>

  <Contributor iid="contrib15">
    <Person><First>Richard</First><Middle>A</Middle><Last>Proctor</Last></Person>
  </Contributor>

  <Contributor iid="contrib16">
    <Person><First>Patrice</First><Last>François</Last></Person>
  </Contributor>

  <Database iid="GEO">
    <Name>Gene Expression Omnibus (GEO)</Name>
    <Public-ID>GEO</Public-ID>
    <Organization>NCBI NLM NIH</Organization>
    <Web-Link>http://www.ncbi.nlm.nih.gov/geo</Web-Link>
    <Email>geo@ncbi.nlm.nih.gov</Email>
  </Database>

  <Platform iid="GPL7137">
    <Status database="GEO">
      <Submission-Date>2008-08-05</Submission-Date>
      <Release-Date>2008-11-07</Release-Date>
      <Last-Update-Date>2011-08-11</Last-Update-Date>
    </Status>
    <Title>Agilent-017903 Staphylococcus aureus V5 Bis 15K (basic)</Title>
    <Accession database="GEO">GPL7137</Accession>
    <Technology>in situ oligonucleotide</Technology>
    <Distribution>custom-commercial</Distribution>
    <Organism taxid="1280">Staphylococcus aureus</Organism>
    <Organism taxid="93061">Staphylococcus aureus subsp. aureus NCTC 8325</Organism>
    <Organism taxid="93062">Staphylococcus aureus subsp. aureus COL</Organism>
    <Organism taxid="158878">Staphylococcus aureus subsp. aureus Mu50</Organism>
    <Organism taxid="158879">Staphylococcus aureus subsp. aureus N315</Organism>
    <Organism taxid="196620">Staphylococcus aureus subsp. aureus MW2</Organism>
    <Organism taxid="282458">Staphylococcus aureus subsp. aureus MRSA252</Organism>
    <Organism taxid="282459">Staphylococcus aureus subsp. aureus MSSA476</Organism>
    <Organism taxid="367830">Staphylococcus aureus subsp. aureus USA300</Organism>
    <Manufacturer>Agilent</Manufacturer>
    <Manufacture-Protocol>
Sure Print Technology-In situ synthesis
    </Manufacture-Protocol>
    <Support>glass</Support>
    <Coating>unknown</Coating>
    <Description>
60-mers oligonucleotide probes, in-situ synthesis
    </Description>
    <Contributor-Ref ref="contrib2" position="1" />
    <Contributor-Ref ref="contrib3" position="2" />
    <Contributor-Ref ref="contrib4" position="3" />
    <Contact-Ref ref="contrib1" />
    <Data-Table>
      <Column position="1">
        <Name>ID</Name>
      </Column>
      <Column position="2">
        <Name>ORF_LIST</Name>
        <Description>Locus tag  </Description>
        <Link-Prefix>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&amp;DB=gene&amp;cmd=search&amp;term=</Link-Prefix>
        <Link-Delimiter>,</Link-Delimiter>
      </Column>
      <Column position="3">
        <Name>Staphylococcus aureus [N315]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus N315 (NC_002745)</Description>
      </Column>
      <Column position="4">
        <Name>Staphylococcus aureus [COL]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus COL (NC_002951)</Description>
      </Column>
      <Column position="5">
        <Name>Staphylococcus aureus [MRSA252]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus MRSA252 (NC_002952)</Description>
      </Column>
      <Column position="6">
        <Name>Staphylococcus aureus [MSSA476]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus MSSA476 (NC_002953)</Description>
      </Column>
      <Column position="7">
        <Name>Staphylococcus aureus [Mu50]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus Mu50 (NC_002758)</Description>
      </Column>
      <Column position="8">
        <Name>Staphylococcus aureus [MW2]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus MW2 (NC_003923)</Description>
      </Column>
      <Column position="9">
        <Name>Staphylococcus aureus [NCTC8325]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus NCTC8325 (NC_007795)</Description>
      </Column>
      <Column position="10">
        <Name>Staphylococcus aureus plasmid [pCOL]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pCOL (NC_006629)</Description>
      </Column>
      <Column position="11">
        <Name>Staphylococcus aureus plasmid [pMu50]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pMu50 (NC_002774)</Description>
      </Column>
      <Column position="12">
        <Name>Staphylococcus aureus plasmid [pN315]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pN315 (NC_003140)</Description>
      </Column>
      <Column position="13">
        <Name>Staphylococcus aureus plasmid [pSAS]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pSAS (NC_005951)</Description>
      </Column>
      <Column position="14">
        <Name>Staphylococcus aureus plasmid [pUSA01]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pUSA01 (NC_007790)</Description>
      </Column>
      <Column position="15">
        <Name>Staphylococcus aureus plasmid [pUSA02]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pUSA02 (NC_007791)</Description>
      </Column>
      <Column position="16">
        <Name>Staphylococcus aureus plasmid [pUSA03]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus plasmid pUSA03 (NC_007792)</Description>
      </Column>
      <Column position="17">
        <Name>Staphylococcus aureus [USA300]</Name>
        <Description>ORF Annotation for genome Staphylococcus aureus USA300 (NC_007793)</Description>
      </Column>
    <External-Data rows="6608">
GPL7137-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Platform>

  <Sample iid="GSM709602">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2011-12-02</Last-Update-Date>
    </Status>
    <Title>Daptomycin suceptible strain WT 5 hours growth replicate 1</Title>
    <Accession database="GEO">GSM709602</Accession>
    <Type>mixed</Type>
    <Channel-Count>2</Channel-Count>
    <Channel position="1">
      <Source>S. aureus 616 WT</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="strain">
616
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 3</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Channel position="2">
      <Source>gDNA pool</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="reference">
Staphylococcus aureus gDNA mixture
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>genomic DNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 5</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
A mixture of RNA from WT or DAPR strains and gDNA pool was diluted in 50 µl Agilent hybridization buffer, and hybridized at a temperature of 60°C for 17 hours in a dedicated hybridization oven.
    </Hybridization-Protocol>
    <Scan-Protocol>
100% PMT using Agilent scanner
    </Scan-Protocol>
    <Description>
Staphylococcus aureus daptomycin suceptible strain 616 WT versus Staphylococcus aureus gDNA pool
    </Description>
    <Data-Processing>
Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labelled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method.
    </Data-Processing>
    <Platform-Ref ref="GPL7137" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM709nnn/GSM709602/GSM709602_616_5h_cy3_vs_pool_gDNA_cy5_1_1.txt.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>Normalized log10 ratio (cy5/cy3)</Description>
      </Column>
    <External-Data rows="6608">
GSM709602-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM709603">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2011-12-02</Last-Update-Date>
    </Status>
    <Title>Daptomycin suceptible strain WT 5 hours growth replicate 2</Title>
    <Accession database="GEO">GSM709603</Accession>
    <Type>mixed</Type>
    <Channel-Count>2</Channel-Count>
    <Channel position="1">
      <Source>S. aureus 616 WT</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="strain">
616
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 3</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Channel position="2">
      <Source>gDNA pool</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="reference">
Staphylococcus aureus gDNA mixture
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>genomic DNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 5</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
A mixture of RNA from WT or DAPR strains and gDNA pool was diluted in 50 µl Agilent hybridization buffer, and hybridized at a temperature of 60°C for 17 hours in a dedicated hybridization oven.
    </Hybridization-Protocol>
    <Scan-Protocol>
100% PMT using Agilent scanner
    </Scan-Protocol>
    <Description>
Staphylococcus aureus daptomycin suceptible strain 616 WT versus Staphylococcus aureus gDNA pool
    </Description>
    <Data-Processing>
Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labelled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method.
    </Data-Processing>
    <Platform-Ref ref="GPL7137" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM709nnn/GSM709603/GSM709603_616_5h_cy3_vs_pool_gDNA_cy5_1_2.txt.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>Normalized log10 ratio (cy5/cy3)</Description>
      </Column>
    <External-Data rows="6608">
GSM709603-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM709604">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2011-12-02</Last-Update-Date>
    </Status>
    <Title>Daptomycin suceptible strain WT 5 hours growth replicate 3</Title>
    <Accession database="GEO">GSM709604</Accession>
    <Type>mixed</Type>
    <Channel-Count>2</Channel-Count>
    <Channel position="1">
      <Source>S. aureus 616 WT</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="strain">
616
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 3</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Channel position="2">
      <Source>gDNA pool</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="reference">
Staphylococcus aureus gDNA mixture
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>genomic DNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 5</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
A mixture of RNA from WT or DAPR strains and gDNA pool was diluted in 50 µl Agilent hybridization buffer, and hybridized at a temperature of 60°C for 17 hours in a dedicated hybridization oven.
    </Hybridization-Protocol>
    <Scan-Protocol>
100% PMT using Agilent scanner
    </Scan-Protocol>
    <Description>
Staphylococcus aureus daptomycin suceptible strain 616 WT versus Staphylococcus aureus gDNA pool
    </Description>
    <Data-Processing>
Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labelled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method.
    </Data-Processing>
    <Platform-Ref ref="GPL7137" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM709nnn/GSM709604/GSM709604_616_5h_cy3_vs_pool_gDNA_cy5_1_3.txt.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>Normalized log10 ratio (cy5/cy3)</Description>
      </Column>
    <External-Data rows="6608">
GSM709604-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM709605">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2011-12-02</Last-Update-Date>
    </Status>
    <Title>Daptomycin non-suceptible strain DAPR 5 hours growth replicate 1</Title>
    <Accession database="GEO">GSM709605</Accession>
    <Type>mixed</Type>
    <Channel-Count>2</Channel-Count>
    <Channel position="1">
      <Source>S. aureus 701 DAPR</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="strain">
701
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 3</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Channel position="2">
      <Source>gDNA pool</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="reference">
Staphylococcus aureus gDNA mixture
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>genomic DNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 5</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
A mixture of RNA from WT or DAPR strains and gDNA pool was diluted in 50 µl Agilent hybridization buffer, and hybridized at a temperature of 60°C for 17 hours in a dedicated hybridization oven.
    </Hybridization-Protocol>
    <Scan-Protocol>
100% PMT using Agilent scanner
    </Scan-Protocol>
    <Description>
Staphylococcus aureus daptomycin non-suceptible strain 701 DAPR versus Staphylococcus aureus gDNA pool
    </Description>
    <Data-Processing>
Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labelled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method.
    </Data-Processing>
    <Platform-Ref ref="GPL7137" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM709nnn/GSM709605/GSM709605_701_5h_cy3_vs_pool_gDNA_cy5_2_2.txt.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>Normalized log10 ratio (cy5/cy3)</Description>
      </Column>
    <External-Data rows="6608">
GSM709605-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM709606">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2011-12-02</Last-Update-Date>
    </Status>
    <Title>Daptomycin non-suceptible strain DAPR 5 hours growth replicate 2</Title>
    <Accession database="GEO">GSM709606</Accession>
    <Type>mixed</Type>
    <Channel-Count>2</Channel-Count>
    <Channel position="1">
      <Source>S. aureus 701 DAPR</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="strain">
701
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 3</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Channel position="2">
      <Source>gDNA pool</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="reference">
Staphylococcus aureus gDNA mixture
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>genomic DNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 5</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
A mixture of RNA from WT or DAPR strains and gDNA pool was diluted in 50 µl Agilent hybridization buffer, and hybridized at a temperature of 60°C for 17 hours in a dedicated hybridization oven.
    </Hybridization-Protocol>
    <Scan-Protocol>
100% PMT using Agilent scanner
    </Scan-Protocol>
    <Description>
Staphylococcus aureus daptomycin non-suceptible strain 701 DAPR versus Staphylococcus aureus gDNA pool
    </Description>
    <Data-Processing>
Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labelled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method.
    </Data-Processing>
    <Platform-Ref ref="GPL7137" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM709nnn/GSM709606/GSM709606_701_5h_cy3_vs_pool_gDNA_cy5_2_3.txt.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>Normalized log10 ratio (cy5/cy3)</Description>
      </Column>
    <External-Data rows="6608">
GSM709606-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM709607">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2011-12-02</Last-Update-Date>
    </Status>
    <Title>Daptomycin non-suceptible strain DAPR 5 hours growth replicate 3</Title>
    <Accession database="GEO">GSM709607</Accession>
    <Type>mixed</Type>
    <Channel-Count>2</Channel-Count>
    <Channel position="1">
      <Source>S. aureus 701 DAPR</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="strain">
701
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 3</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Channel position="2">
      <Source>gDNA pool</Source>
      <Organism taxid="1280">Staphylococcus aureus</Organism>
      <Characteristics tag="reference">
Staphylococcus aureus gDNA mixture
      </Characteristics>
      <Treatment-Protocol>
no treatments
      </Treatment-Protocol>
      <Growth-Protocol>
5 hours growth in Muller-Hinton
      </Growth-Protocol>
      <Molecule>genomic DNA</Molecule>
      <Extract-Protocol>
RNAprotectTM Bacteria Reagent (Qiagen, Hilden, Germany) and immediately incubated on ice. After centrifugation for 10 min at 6.000 x g and 4°C, the supernatant was discarded and the pellet resuspended in 1 ml RLT-buffer (Qiagen) supplemented with 1 % (vol/vol) β-mercaptoethanol. Cells were disrupted in Lysing Matrix E (MP Biomedicals) using a FastPrep®-24 (MP Biomedicals, Solon, OH, USA), followed by cooling on ice for 2 min. After brief centrifugation, the supernatant was purified using RNeasy®Mini Kit. Final treatment with DNase for 1 h at 37°C and again purified with RNeasy®Mini Kit.
      </Extract-Protocol>
      <Label>cyanine 5</Label>
      <Label-Protocol>
Incorporation during reverse transcription
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
A mixture of RNA from WT or DAPR strains and gDNA pool was diluted in 50 µl Agilent hybridization buffer, and hybridized at a temperature of 60°C for 17 hours in a dedicated hybridization oven.
    </Hybridization-Protocol>
    <Scan-Protocol>
100% PMT using Agilent scanner
    </Scan-Protocol>
    <Description>
Staphylococcus aureus daptomycin non-suceptible strain 701 DAPR versus Staphylococcus aureus gDNA pool
    </Description>
    <Data-Processing>
Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labelled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method.
    </Data-Processing>
    <Platform-Ref ref="GPL7137" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM709nnn/GSM709607/GSM709607_701_5h_cy3_vs_pool_gDNA_cy5_2_4.txt.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>Normalized log10 ratio (cy5/cy3)</Description>
      </Column>
    <External-Data rows="6608">
GSM709607-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Series iid="GSE28632">
    <Status database="GEO">
      <Submission-Date>2011-04-14</Submission-Date>
      <Release-Date>2011-12-02</Release-Date>
      <Last-Update-Date>2012-03-23</Last-Update-Date>
    </Status>
    <Title>Daptomycin-Resistance Mechanisms in Clinically-Derived Staphylococcus aureus Strains Assessed by a Combined Transcriptomics and Proteomics Approach</Title>
    <Accession database="GEO">GSE28632</Accession>
    <Pubmed-ID>21622973</Pubmed-ID>
    <Summary>
Objectives: Development of daptomycin resistance (DAPR) in Staphylococcus aureus is associated with clinical treatment failures. Mechanism(s) of such resistance has not been clearly defined.

Methods: We studied an isogenic daptomycin-susceptible (DAPS) and daptomycin-resistant (DAPR) S. aureus strain pair (616; 701) from a patient with relapsing endocarditis during daptomycin treatment, using comparative transcriptomic and proteomic techniques.   Results. Minor differences in genome content were found between strains by DNA hybridization. Transcriptomic analyses identified a number of genes differentially expressed in important functional categories: cell division, metabolism of bacterial envelopes and global regulation. Of note, the DAPR isolate exhibited reduced expression of the major cell wall autolysis gene coincident with upregulation of genes involved in wall teichoic acid production. Using quantitative (q)RT-PCR on gene cadre putatively involved in cationic peptide resistance, we formulated a putative regulatory network compatible with microarray data-sets, mainly implicating bacterial envelopes. Of interest, qRT-PCR of this same gene cadre from two distinct isogenic DAPS/DAPR clinical strain pairs revealed evidence of other strain dependent networks operative in the DAPR phenotype. Comparative proteomics of 616 vs 701 revealed differential abundance of proteins in various functional categories including: cell-wall associated targets and biofilm-formation proteins. Phenotypically, strains 616 and 701 showed major differences in ability to develop bacterial biofilms in presence of the antibacterial lipid, oleic acid.

Conclusions: Compatible with previous in vitro observations, in vivo acquired DAPR in S. aureus is a complex, multistep phenomenon allowing for: i) strain dependent phenotypes; ii) transcriptome adaptation; and iii) modification of lipid and protein content of cellular envelopes.
    </Summary>
    <Overall-Design>
Daptomycin suceptible strain vs daptomycin non suceptible strain after daptomycin treatment
    </Overall-Design>
    <Type>Expression profiling by array</Type>
    <Contributor-Ref ref="contrib5" position="1" />
    <Contributor-Ref ref="contrib6" position="2" />
    <Contributor-Ref ref="contrib7" position="3" />
    <Contributor-Ref ref="contrib8" position="4" />
    <Contributor-Ref ref="contrib9" position="5" />
    <Contributor-Ref ref="contrib10" position="6" />
    <Contributor-Ref ref="contrib11" position="7" />
    <Contributor-Ref ref="contrib12" position="8" />
    <Contributor-Ref ref="contrib13" position="9" />
    <Contributor-Ref ref="contrib14" position="10" />
    <Contributor-Ref ref="contrib15" position="11" />
    <Contributor-Ref ref="contrib4" position="12" />
    <Contributor-Ref ref="contrib16" position="13" />
    <Contact-Ref ref="contrib1" />
    <Sample-Ref ref="GSM709602" />
    <Sample-Ref ref="GSM709603" />
    <Sample-Ref ref="GSM709604" />
    <Sample-Ref ref="GSM709605" />
    <Sample-Ref ref="GSM709606" />
    <Sample-Ref ref="GSM709607" />
    <Supplementary-Data type="TAR">
ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/series/GSE28632/GSE28632_RAW.tar
    </Supplementary-Data>
    <Relation type="BioProject" target="http://www.ncbi.nlm.nih.gov/bioproject/138881" />
  </Series>

</MINiML>
